More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia
More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia
复制标题
DOI：
10.1038/sj.leu.2402704
复制
发表时间：
2002-11-01
期刊：
影响因子：
11.4
通讯作者：
Albitar, M
中科院分区：
文献类型：
--
作者：
Huh, YO;Jilani, I;Albitar, M
难治性贫血伴转化中原始细胞过多（RAEB-T）是骨髓增生异常综合征（MDS）的一个亚组，其中骨髓原始细胞计数范围为20%至30%。最近提出的世界卫生组织血液系统恶性肿瘤分类通过将急性髓性白血病（AML）的原始细胞计数截止值从30%降低到20%，从MDS中消除了这一类别。然而，MDS与AML的区别在于细胞凋亡的显著增加。为了研究RAEB-T、AML和其他类型MDS之间细胞凋亡的差异，我们采用膜联蛋白V和线粒体电位测定法前瞻性分析了新鲜骨髓样本。两种检测方法均显示RAEB-T细胞凋亡水平显著高于AML细胞，而RAEB-T细胞与其他类型MDS细胞凋亡水平无显著差异。这些数据表明，RAEB-T更可能是MDS的晚期，并且在生物学上不同于AML。
Refractory anemia with excess blasts in transformation (RAEB-T) is a subgroup of myelodysplastic syndrome (MDS) in which the bone marrow blast count ranges from 20% to 30%. The recently proposed World Health Organization Classification of Hematologic Malignancies eliminated this category from MDS by lowering the blast count cutoff for acute myeloid leukemia (AML) from 30% to 20%. However, MDS is distinguished from AML by a significant increase in apoptosis. To investigate the difference in apoptosis between RAEB-T, AML, and other categories of MDS, we prospectively analyzed fresh bone marrow samples using the Annexin V and mitochondrial potential assays. There was a significantly higher level of apoptosis in RAEB-T than in AML according to both assays, while no significant differences between RAEB-T and other categories of MDS were noted. The data suggest that RAEB-T is more likely to be an advanced stage of MDS and biologically different from AML.